Multiple Sclerosis Drugs Global Market Report 2023

Publish Date: Feb 2023

Report Code: TBR761D

Publisher: TBRC (Publisher)

Single User License: $5000

Explore Our Services

Already a member? Login here.

Report Highlights

Including: 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons
2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores
3) By Route Of Administration: Oral Drugs; Parenteral Drugs
Covering: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer Inc.

Multiple Sclerosis Drugs Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on multiple sclerosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description:
Where is the largest and fastest growing market for multiple sclerosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The multiple sclerosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2032
Units considered $ Billion
Segments covered By Drug Class, By Distribution Channels, By Route Of Administration
Industry covered Pharmaceuticals
Regions covered Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Countries covered Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
Companies studied
  • Biogen
  • CinnoVex
  • Pfizer Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline
  • Acorda Therapeutics Inc.
  • Actelion Pharmaceutical
  • EMD Serono
  • AbbVie Inc.
  • Betaseron
  • Extavia
  • Rebif
  • Novartis
  • Roche
  • Bayer HealthCare
  • Tysabr
  • Merck & Co. Inc.
  • Sanofi

Scope

Markets Covered:

  • By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Other Drug Classes
  • By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores
  • By Route Of Administration: Oral Drugs; Parenteral Drugs

Companies Mentioned: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

  • Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3 : Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4 : Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5 : Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6 : Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7 : Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8 : Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9 : Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10 : China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11 : China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12 : India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13 : India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14 : Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15 : Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16 : Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17 : Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18 : Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19 : Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20 : South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21 : South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22 : Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23 : Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24 : UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25 : UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26 : Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27 : Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28 : France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29 : France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30 : Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31 : Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32 : Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33 : Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34 : North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35 : North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36 : USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37 : USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38 : South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39 : South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40 : Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41 : Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42 : Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43 : Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44 : Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45 : Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46 : Biogen Financial Performance
  • Table 47 : Novartis Financial Performance
  • Table 48 : Roche Financial Performance
  • Table 49 : Bayer HealthCare Financial Performance
  • Table 50 : Pfizer, Inc. Financial Performance
  • Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3 : Global Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4 : Global Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5 : Global Multiple Sclerosis Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6 : Global Multiple Sclerosis Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7 : Global Multiple Sclerosis Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8 : Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9 : Asia-Pacific, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10 : China, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11 : China, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12 : India, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13 : India, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14 : Japan, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15 : Japan, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16 : Australia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17 : Australia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18 : Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19 : Indonesia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20 : South Korea, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21 : South Korea, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22 : Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23 : Western Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24 : UK, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25 : UK, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26 : Germany, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27 : Germany, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28 : France, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29 : France, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30 : Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31 : Eastern Europe, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32 : Russia, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33 : Russia, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34 : North America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35 : North America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36 : USA, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37 : USA, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38 : South America, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39 : South America, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40 : Brazil, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41 : Brazil, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42 : Middle East, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43 : Middle East, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44 : Africa, Multiple Sclerosis Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45 : Africa, Multiple Sclerosis Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46 : Biogen Financial Performance
  • Figure 47 : Novartis Financial Performance
  • Figure 48 : Roche Financial Performance
  • Figure 49 : Bayer HealthCare Financial Performance
  • Figure 50 : Pfizer, Inc. Financial Performance

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

Multiple Sclerosis Drugs Global Market Report 2022

  • Date - Mar 2022
  • Code - TBR761C

Including: 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others
2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores
3) By Route Of Administration: Oral Drugs; Parenteral Drugs
Covering: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer inc.; Merck & Co. inc.; Sanofi; Teva Pharmaceutical Industries Ltd.

Multiple Sclerosis Drugs Global Market Report 2022 from The Business Research Company ...

Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth And Change To 2030

  • Date - Sep 2021
  • Code - TBR761B

Including: 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others
2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores
3) By Route Of Administration: Oral Drugs; Parenteral Drugs
Covering: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.

Multiple Sclerosis Drugs Global Market Report 2021: COVID-19 Growth And Change to 2030 from The Business Research Company provides the strategists, ...

Multiple Sclerosis Drugs Market Global Report 2020-30

  • Date - Apr 2020
  • Code - TBR761A

Including: 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others; 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores; 3) By Route Of Administration: Oral Drugs; Parenteral Drugs

Covering: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.

Become A Member

BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.

Find Out More

Custom Consulting

BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.

Customize Now

Scorecard

The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.

Find Out More

Innovation Spotlight

Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.

Find Out More
Multiple Sclerosis Drugs Global Market Report 2023